AstraZeneca has committed $2 billion (£1.5 billion) to Summit Therapeutics, a US-based pharmaceutical company, to support a collaborative effort focused on developing novel cancer treatments. The investment, announced on Wednesday, is part of a joint venture aimed at advancing Summit’s experimental drug, ivonescimab, which is designed to inhibit cancer cell growth by targeting specific proteins.

The financial infusion from AstraZeneca, which is listed on the London Stock Exchange, is intended to accelerate the clinical development of ivonescimab. The two companies plan to explore the potential of combining this investigational therapy with AstraZeneca’s existing treatment, Sone-Ve, to enhance efficacy against cancer.

Initial clinical trials targeting gastrointestinal cancers are expected to commence shortly, marking a significant step in evaluating the new drug combination’s effectiveness and safety. Both AstraZeneca and Summit Therapeutics are focusing on the promise of this approach to deliver targeted therapeutic options for patients with difficult-to-treat cancers.

The collaboration highlights ongoing efforts within the pharmaceutical industry to innovate by leveraging complementary drug candidates and expertise to address unmet medical needs in oncology. Further details on trial design, timelines, and projected milestones are anticipated as the development program progresses.